[关键词]
[摘要]
年龄相关性黄斑变性(ARMD)是中老年人不可逆性视力损害的一种主要原因，严重影响个人生活质量并加重社会卫生经济负担。晚期ARMD在临床上有两种表现类型，即干性ARMD(dARMD)和湿性ARMD(nARMD)。nARMD以抗血管内皮生长因子作为一线药物已取得显著疗效，而dARMD尚无确切的治疗方法。本文就dARMD在临床试验中取得显著进展、可望上市的潜在药物、生物疗法和中医中药进行综述，包括抗炎药(强力霉素和FHTR2163)、抗氧化药(利舒尼布和依来米普瑞肽)、补体抑制剂(APL-2和滋目若)、视觉周期调节剂(ALK-001)、神经保护剂(溴莫尼定)、干细胞移植(MA09-hRPE和BMMF)、基因疗法(HMR59)和中医中药(藏红花、姜黄素、槲皮素和白藜芦醇)等。这些药物临床试验疗效显著，应用前景广阔，为ARMD改善与治疗带来巨大希望。
[Key word]
[Abstract]
Age-related macular degeneration(ARMD)is one of the main causes of irreversible visual impairment in the middle-aged and elderly people, which severely impacts the patient's life quality and poses a substantial health economic burden on society. There are two types of late ARMD in clinic: wet ARMD and dry ARMD. Anti-vascular endothelial growth factor drugs, as first-line clinical drugs for wet ARMD, achieved remarkable efficacy. For dry ARMD, however, effective therapies are in the air. This review focuses on the potential drugs, biological therapies and traditional Chinese medicines that made significant progresses in clinical trials for dry ARMD, including anti-inflammatory drugs(doxycycline and FHTR2163), anti-oxidants(risuteganib and elamipretide), complement inhibitors(APL-2 and zimura), visual cycle modulators(ALK-001), neuroprotective agents(brimonidine), stem cell transplantation(MA09-hRPE and BMMF), gene therapy(HMR59), and traditional Chinese medicine(saffron, curcumin, quercetin and resveratrol). The new drugs exhibited favorable clinical efficacy and broad application prospects, which would foster hope for improvement and treatment of ARMD.
[中图分类号]
[基金项目]
陕西省教育厅2019年度重点科学研究计划项目(No.19JS058); 国家自然科学基金项目(No.U1932130); 陕西省科技厅2021年度自然科学青年基金项目(No.2021JQ-788); 西安医学院博士基金项目(No.2018DOC10)
